Home > Research > Publications & Outputs > A plea for precaution with public health : the ...

Research

Associated organisational unit

Links

Text available via DOI:

View graph of relations

A plea for precaution with public health : the xenotransplantation example.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

A plea for precaution with public health : the xenotransplantation example. / Fovargue, Sara; Ost, Suzanne.
In: Clinical Ethics, Vol. 4, No. 3, 09.2009, p. 119-124.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Fovargue, S & Ost, S 2009, 'A plea for precaution with public health : the xenotransplantation example.', Clinical Ethics, vol. 4, no. 3, pp. 119-124. https://doi.org/10.1258/ce.2009.009017

APA

Fovargue, S., & Ost, S. (2009). A plea for precaution with public health : the xenotransplantation example. Clinical Ethics, 4(3), 119-124. https://doi.org/10.1258/ce.2009.009017

Vancouver

Fovargue S, Ost S. A plea for precaution with public health : the xenotransplantation example. Clinical Ethics. 2009 Sept;4(3):119-124. doi: 10.1258/ce.2009.009017

Author

Fovargue, Sara ; Ost, Suzanne. / A plea for precaution with public health : the xenotransplantation example. In: Clinical Ethics. 2009 ; Vol. 4, No. 3. pp. 119-124.

Bibtex

@article{dc2630c4f7cf4805af7fa1a44298736d,
title = "A plea for precaution with public health : the xenotransplantation example.",
abstract = "In this paper we argue that while individual private interests such as autonomy and the need for a medical procedure or treatment are important in the provision and delivery of health care and the utilization of biotechnologies, these concepts need to be balanced with other interests such that in certain situations they do not take priority. We use as an example a particular developing biotechnology, xenotransplantation, to suggest that interest in the health of the public is such that this biotechnology should not be permitted to move to the clinical trial stage because of the particular risk of harm it poses to the potential xeno-recipient, their close contacts and the wider population. This is despite the interest of those in need of a transplant in allowing such clinical trials to proceed. We derive support for our position from John Stuart Mill's harm principle.",
author = "Sara Fovargue and Suzanne Ost",
year = "2009",
month = sep,
doi = "10.1258/ce.2009.009017",
language = "English",
volume = "4",
pages = "119--124",
journal = "Clinical Ethics",
issn = "1758-101X",
publisher = "SAGE Publications Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - A plea for precaution with public health : the xenotransplantation example.

AU - Fovargue, Sara

AU - Ost, Suzanne

PY - 2009/9

Y1 - 2009/9

N2 - In this paper we argue that while individual private interests such as autonomy and the need for a medical procedure or treatment are important in the provision and delivery of health care and the utilization of biotechnologies, these concepts need to be balanced with other interests such that in certain situations they do not take priority. We use as an example a particular developing biotechnology, xenotransplantation, to suggest that interest in the health of the public is such that this biotechnology should not be permitted to move to the clinical trial stage because of the particular risk of harm it poses to the potential xeno-recipient, their close contacts and the wider population. This is despite the interest of those in need of a transplant in allowing such clinical trials to proceed. We derive support for our position from John Stuart Mill's harm principle.

AB - In this paper we argue that while individual private interests such as autonomy and the need for a medical procedure or treatment are important in the provision and delivery of health care and the utilization of biotechnologies, these concepts need to be balanced with other interests such that in certain situations they do not take priority. We use as an example a particular developing biotechnology, xenotransplantation, to suggest that interest in the health of the public is such that this biotechnology should not be permitted to move to the clinical trial stage because of the particular risk of harm it poses to the potential xeno-recipient, their close contacts and the wider population. This is despite the interest of those in need of a transplant in allowing such clinical trials to proceed. We derive support for our position from John Stuart Mill's harm principle.

U2 - 10.1258/ce.2009.009017

DO - 10.1258/ce.2009.009017

M3 - Journal article

VL - 4

SP - 119

EP - 124

JO - Clinical Ethics

JF - Clinical Ethics

SN - 1758-101X

IS - 3

ER -